KDM1A and neoplasm: Scientists accomplished this method by modifyinga cytotoxic T cell line to overexpress programmed death receptor 1and employing their membrane to encapsulate protein NPs that carriedORY-1001, a lysine-specific histone demethylase 1 (LSD1) inhibitor.Following intravenous treatment, the OPEN facilitated the accumulationof ORY-1001 within tumors and production of IFNs, which subsequentlystimulated the infiltration, activation, proliferation, and presentationof tumor-specific cytotoxic T cells and tumor cell antigen.